217973-05-2

Basic information

• Product Name: Hexahydro-3-methyl-2H-1,4-diazepin-2-one
• Synonyms: Hexahydro-3-methyl-2H-1,4-diazepin-2-one;3-Methyl-[1,4]diazepan-2-one
• CAS NO: 217973-05-2
• Molecular Formula: C6H12N2O
• Molecular Weight: 128
• Mol File: 217973-05-2.mol

Chemical Properties

• Boiling Point: 299.6±33.0 °C(Predicted)
• Appearance: /
• Density: 0.965
• PKA: 15.91±0.40(Predicted)
• CAS DataBase Reference: Hexahydro-3-methyl-2H-1,4-diazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: Hexahydro-3-methyl-2H-1,4-diazepin-2-one(217973-05-2)
• EPA Substance Registry System: Hexahydro-3-methyl-2H-1,4-diazepin-2-one(217973-05-2)

Safety Data

• Hazardous Substances Data: 217973-05-2(Hazardous Substances Data)

Upstream product

• 685858-98-4 tert-butyl (2R)-hexahydro-2-methyl-3-oxo-1H-1,4-diazepine-1-carboxylate 
• 685858-96-2 (R)-methyl 2-[(tert-butoxycarbonyl)(2-cyanoethyl)amino]propanoate 
• 685858-97-3 (R)-methyl 2-[(tert-butoxycarbonyl)(3-aminopropyl)amino]propanoate 

Downstream Products

• 65974-17-6 2-Methyl-hexahydro-1H-1,4-diazepine 

Relevant articles and documents

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Following the discovery of N-acyl-1,4-diazepan-2-one as a novel pharmacophore for potent and selective DPP-4 inhibitors, optimization of this new lead with different substitution on the seven-membered ring resulted in several highly potent and selective,

ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

This invention relates to isoquinolinesulfonamide derivatives represented by the following formula (1): wherein A represents a linear or branched alkylene group, R1 represents a hydrogen atom, an hydroxyl, alkoxy or alkyl group or the like, R2 represents a hydrogen atom, an alkyl group or the like, R3 represents a hydrogen atom, an alkyl group or the like, and R4 and R5 may be the same or different and individually represent hydrogen atoms or lower alkyl groups; N-oxides and salts thereof; and solvates thereof. This invention is also concerned with pharmaceutical compositions, which contain the derivatives, N-oxides, salts, or solvates. These derivatives, N-oxides, salts, and solvates have viral proliferation inhibiting activities and are useful as AIDS therapeutics.